SAN DIEGO, May 14, 2026 /PRNewswire/ — Inhibrx Biosciences, Inc. (Nasdaq: INBX) (“Inhibrx” or the “Company”) today reported financial results for the first quarter of 2026. The biopharmaceutical company has two programs in ongoing clinical trials. Recent Corporate Highlights and Upcoming…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
